FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

IGF-1 LR3

Long R3 IGF-1 / LR3-IGF-1 / Insulin-like Growth Factor 1 Long R3

Growth Factors

IGF-1 LR3 (Long Arg3 IGF-1) is a modified version of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino acid extension at the N-terminus, resulting in significantly reduced binding to IGF-binding proteins. This modification increases its bioavailability and half-life from minutes to approximately 20-30 hours, making it one of the most potent growth factors available for research. It promotes muscle hypertrophy, hyperplasia, and enhanced nutrient uptake in target tissues.

作用機序

Modified form of IGF-1 with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications prevent IGF binding protein (IGFBP) sequestration, dramatically increasing bioavailability and potency compared to native IGF-1.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 20-60mcg daily via subcutaneous or intramuscular injection. Often administered post-workout. Cycles limited to 4-6 weeks due to potency. Splitting dose bilaterally may improve localized effects.

研究ノート

Clinical Research Status

IGF-1 LR3 is a research-grade compound that has not undergone formal clinical development for any therapeutic indication. Native IGF-1 (mecasermin/Increlex) is FDA-approved for severe IGF-1 deficiency, but the LR3 variant has no regulatory pathway. It is used extensively in cell culture and in vitro research due to its potent proliferative effects and reduced binding protein interference. No Phase 1 human trials of IGF-1 LR3 specifically have been conducted.

Key Published Findings

In vitro and animal studies demonstrate IGF-1 LR3 has approximately 2-3 times the potency of native IGF-1 due to its reduced sequestration by IGF-binding proteins (particularly IGFBP-3). Research shows it activates the PI3K/Akt and MAPK pathways promoting both muscle protein synthesis and satellite cell proliferation (hyperplasia). Unlike GH which acts systemically, IGF-1 LR3 has direct anabolic effects on muscle tissue without requiring hepatic conversion.

Safety Profile

IGF-1 LR3 carries a higher risk profile than most peptides due to its potent, long-acting proliferative effects on all tissues including potentially cancerous cells. Hypoglycemia is a significant acute risk due to insulin-like metabolic activity, particularly at higher doses or with concurrent insulin use. Long-term concerns include potential acceleration of undetected neoplasms, organ growth (intestinal hypertrophy), and insulin receptor desensitization. No human safety data exists for this specific variant.

Comparison to Related Compounds

Compared to native IGF-1 (mecasermin), IGF-1 LR3 has dramatically extended half-life and higher free-fraction concentration due to poor IGFBP binding. Relative to GH or GH-releasing peptides, IGF-1 LR3 bypasses the entire GH/IGF axis and acts directly, producing more predictable but less physiological tissue growth. Unlike MGF (a splice variant focused on muscle repair), IGF-1 LR3 has broader systemic anabolic effects on multiple tissue types.

Community Observations

IGF-1 LR3 is considered among the highest-risk peptides in research circles due to its non-selective proliferative effects and lack of human safety data. Users report pronounced muscle fullness and accelerated recovery, but also significant hypoglycemia risk requiring careful carbohydrate management. The research community emphasizes that its growth-promoting effects are not tissue-specific, raising concerns about intestinal polyp growth, cardiac hypertrophy, and tumor promotion.

半減期

~20-30 hours

再構成

Bacteriostatic water (BAC) or 0.6% acetic acid

保存

乾燥粉末

Refrigerate 2-8C up to 24 months.

再溶解

Refrigerate 2-8C. Use within 14 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

Long R3 IGF-1LR3-IGF-1Insulin-like Growth Factor 1 Long R3

よくある質問

IGF-1 LR3とは何ですか?

IGF-1 LR3 (Long Arg3 IGF-1) is a modified version of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino acid extension at the N-terminus, resulting in significantly reduced binding to IGF-binding proteins. This modification increases its bioavailability and half-life from minutes to approximately 20-30 hours, making it one of the most potent growth factors available for research. It promotes muscle hypertrophy, hyperplasia, and enhanced nutrient uptake in target tissues.

IGF-1 LR3はどのように作用しますか?

Modified form of IGF-1 with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications prevent IGF binding protein (IGFBP) sequestration, dramatically increasing bioavailability and potency compared to native IGF-1.

IGF-1 LR3の米国での規制状況は?

Research chemical (not FDA-approved)

IGF-1 LR3の半減期は?

~20-30 hours

IGF-1 LR3の別名は?

Long R3 IGF-1, LR3-IGF-1, Insulin-like Growth Factor 1 Long R3

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む